Seeone
Lv612
2768 积分
2022-08-01 加入
-
Antibody Drug Conjugates in Urological Cancers: A Review of the Current Landscape
8天前
已完结
-
Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial
9天前
已完结
-
The antibody–drug conjugate landscape
14天前
已完结
-
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
17天前
已完结
-
Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial
17天前
已完结
-
Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial
17天前
已完结
-
Progress of antibody–drug conjugates (ADCs) targeting c-Met in cancer therapy; insights from clinical and preclinical studies
21天前
已完结
-
Food is medicine: clinical trials show the health benefits of dietary interventions
21天前
已完结
-
The present and future of bispecific antibodies for cancer therapy
21天前
已完结
-
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
22天前
已完结